{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"275.05","value":"183.94"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 30, 181.54, 1082.74, 122.03, 10, 120, 22.5 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 510.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"351.83","value":"186.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"69"}],"units":"Participants"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"270.67","value":"177.98"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 30, 182.4, 1082.22, 120.96, 10, 120, 22.5 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 510.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"356.15","value":"188.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"69"}],"units":"Participants"}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"266.93","value":"177.87"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 34.28, 182.4, 1082.22, 120.96, 52.85, 120, 22.5 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 480.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"349.82","value":"181.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"69"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"280.44","value":"186.20"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 95, 182.4, 1081.54, 120.96, 10, 137.14, 22.5 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 510.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"346.27","value":"173.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"70"}],"units":"Participants"}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"281.01","value":"188.10"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 122.14, 2.4, 1081.71, 120.96, 10, 120, 22.5 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 510.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"327.19","value":"170.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"70"}],"units":"Participants"}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"336.74","value":"187.43"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 258.57, 2.4, 1.2, 88.45, 10, 120, 22.5 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 480.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"332.39","value":"177.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"70"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"333.77","value":"189.62"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 170, 2.4, 1.2, 86.31, 10, 120, 22.5 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 480.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"329.17","value":"173.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"70"}],"units":"Participants"}],"title":"Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"353.10","value":"189.78"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values were 0.3, 170, 2.4, 1.2, 88.45, 74.28, 120, 18.21 and 30.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as Mean and SD.\n\nIndividual values was 480.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"1537.00","value":"346.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"70"}],"units":"Participants"}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"72"}],"units":"Participants"}],"description":"In this outcome measure average daily opioid consumption was reported in milligram of morphine equivalent dose (mg of MED).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received placebo matched to tanezumab SC once every 8 weeks for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants in this discontinued treatment arm, received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and completed their treatment before the amendment.","id":"OG001","title":"Tanezumab 10 mg"},{"description":"Participants in this treatment group had received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and after the amendment they continued remaining treatment with tanezumab 20 mg SC once every 8 weeks.","id":"OG002","title":"Tanezumab 10/20 mg"},{"description":"Participants received tanezumab 20 mg SC once every 8 weeks for 24 weeks.","id":"OG003","title":"Tanezumab 20 mg"}],"paramType":"MEAN","populationDescription":"The mITT analysis set: participants randomized to tanezumab 20 mg or placebo SC, received at least 1dose of SC study medication. LOCF data was applied. As planned summarized efficacy data for tanezumab 10 mg and 10/20 mg arms not reported; for these 2 arms individual values are reported. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure and ''number analyzed'' signifies participants evaluable at specified time points.","reportingStatus":"POSTED","timeFrame":"Weeks 1, 2, 4, 6, 8, 12, 16 and 24","title":"Average Daily Total Opioid Consumption at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","type":"SECONDARY","unitOfMeasure":"mg of MED"}